非小细胞肺癌辅助化疗患者的早期死亡率
该研究利用美国国家癌症数据库分析2004至2012年间接受完全切除后多药辅助化疗的IB-IIIA期NSCLC患者,计算化疗开始后6个月内的累积死亡率。共纳入19691例患者,6个月累积死亡率为4.1%,且年龄>70岁、合并症评分高及术后住院时间延长与早期死亡风险升高独立相关。
要点
- 辅助化疗开始后6个月累积死亡率为4.1%,早期死亡风险随年龄增长而升高。
- 年龄>70岁、Charlson-Deyo合并症评分≥2、男性、全肺切除、术后住院>6天及30天内再入院与6个月死亡率升高独立相关。
- 对高龄、高合并症负担及术后恢复延迟的患者,启动辅助化疗前应充分评估风险。
核心结论
- 完全切除的NSCLC患者接受辅助化疗存在早期死亡风险,6个月累积死亡率为4.1%。
- 年龄>70岁、高合并症评分及术后住院时间延长与6个月死亡率升高独立相关。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004-2012年诊断为IB-IIIA期NSCLC、接受手术切缘阴性完全切除后120天内开始多药辅助化疗的18岁以上患者。
- 共19691例符合标准,其中19398例有已知6个月死亡状态,中位年龄65岁(范围19-89)。
主要发现
- 从化疗开始算起,1、2、3、4、5、6个月累积死亡率分别为0.7%、1.3%、1.9%、2.6%、3.2%、4.1%。
- 各年龄组(≤50岁、51-60、61-70、71-80、>80岁)6个月死亡率分别为2.6%、3.1%、4.1%、5.3%、7.6%(p<0.001)。
- 与<50岁相比,71-80岁(OR=1.72,95%CI 1.16-2.55,p=0.007)和>80岁(OR=2.43,95%CI 1.40-4.20,p=0.002)的6个月死亡率更高。
- 男性(OR=1.42,95%CI 1.21-1.67,p<0.001)、Charlson-Deyo合并症评分2 vs 0(OR=1.52,95%CI 1.22-1.89,p<0.001)、全肺切除(OR=1.38,95%CI 1.11-1.73,p=0.004)、术后住院>6天(OR=1.21,95%CI 1.03-1.41,p=0.02)及术后30天内再入院(OR=1.48,95%CI 1.15-1.90,p=0.02)与6个月死亡率升高独立相关。
临床怎么用
- 启动辅助化疗前应综合评估年龄、合并症、手术方式及术后恢复情况,识别早期死亡高风险患者。
- 对高龄(>70岁)、高合并症评分或术后住院时间延长的患者,需个体化权衡辅助化疗获益与风险。
局限性
- 研究为回顾性数据库分析,可能存在未测量的混杂因素。
- 仅纳入接受辅助化疗的患者,缺乏未化疗对照组的直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although adjuvant chemotherapy improves survival in patients with completely resected NSCLC, it is also associated with potentially disabling or lethal adverse events. Because there is limited information on the early mortality among patients undergoing adjuvant chemotherapy, we used the National Cancer Database to calculate the percentage of deaths within the first 6 months of starting chemotherapy. METHODS: The National Cancer Database was queried for patients age 18 or older in whom stage IB to IIIA NSCLC had been diagnosed between 2004 and 2012 and who had received multiagent adjuvant chemotherapy starting within 120 days from the surgical resection with negative surgical margins. Age groups were divided as follows: younger than 50, 51 to 60, 61 to 70, 71 to 80, and older than 80 years. RESULTS: A total of 19,691 patients met the eligibility criteria, 19,398 of whom had a known 6-month mortality status. The median age was 65 years (range 19-89). The 1-, 2-, 3-, 4-, 5-, and 6-month cumulative mortality rates from initiation of chemotherapy were 0.7%, 1.3%, 1.9%, 2.6%, 3.2%, and 4.1% respectively. The 6-month mortality rates for each age group (≤ 50 years, 51-60, 61-70, 71-80, and >80) were 2.6%, 3.1%, 4.1%, 5.3%, and 7.6%, respectively (p < 0.001). Independent factors associated with increased 6-month mortality included age 71 to 80 versus younger than 50 (OR = 1.72, 95% confidence interval [CI]: 1.16-2.55, p = 0.007), age older than 80 versus younger than 50 (OR = 2.43, 95% CI: 1.40-4.20, p = 0.002), male sex (OR = 1.42; 95% CI: 1.21-1.67, p < 0.001), Charlson-Deyo comorbidity score of 2 versus 0 (OR = 1.52, 95% CI 1.22-1.89, p < 0.001), pneumonectomy (OR = 1.38, 95% CI: 1.11-1.73, p = 0.004), length of postopertive stay longer than 6 days after surgery (OR = 1.21, 95% CI: 1.03-1.41, p = 0.02), and readmission within 30 days from surgery (OR = 1.48, 95% CI: 1.15-1.90, p = 0.02). CONCLUSIONS: Early mortality with the use of adjuvant chemotherapy after complete resection of NSCLC is a clinical concern. The risk is higher in patients older than 70 years, with higher comorbidity scores and a prolonged length of stay postoperatively.
引用
- Morgensztern D, Samson PS, Waqar SN, et al. Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29410127. doi:10.1016/j.jtho.2018.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。